Latest Filings

Issuer Activity

Overview :: McKesson Corporation (N:MCK) [?]
Business Focus: Drug Retailers Share on StockTwits
Recent Price for MCK
USD 170.00 0.00 (0.00%)
NYSE Delayed 15 minutes
Apr 16 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 188.02 34.50 N/A 39,121.55
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 102.68 0.6% 1,379,077  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for MCK within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 8:54am ET April 17th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Mar 25/14 Mar 21/14 Figueredo Jorge Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -23,684  
Mar 25/14 Mar 21/14 Figueredo Jorge Direct Ownership Common Stock S - Open market or private sale -23,684 $185.81
Mar 25/14 Mar 21/14 Figueredo Jorge Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 23,684 $83.51
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -12,500  
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -3,750  
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock S - Open market or private sale -10,000 $180.53
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 10,000 $41.51
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock S - Open market or private sale -28,750 $180.30
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 12,500 $41.51
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 12,500 $40.46
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for MCK within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 8:54am ET April 17th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Mar 25/14 Mar 21/14 Figueredo Jorge Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -23,684  
Mar 25/14 Mar 21/14 Figueredo Jorge Direct Ownership Common Stock S - Open market or private sale -23,684 $185.81
Mar 25/14 Mar 21/14 Figueredo Jorge Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 23,684 $83.51
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -12,500  
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Employee Stock Option (Right-to-buy) M - Exercise or conversion exempt under rule 16b-3 -3,750  
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock S - Open market or private sale -10,000 $180.53
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 10,000 $41.51
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock S - Open market or private sale -28,750 $180.30
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 12,500 $41.51
Mar 12/14 Mar 10/14 Blake Patrick Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 12,500 $40.46
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers
 
See Regulatory Filings on SEC
Key People
John Harvey Hammergren
Chairman of the Board, President, Chief Executive Officer
James A. Beer
Chief Financial Officer, Executive Vice President
Randall N. Spratt
Chief Information Officer, Chief Technology Officer, Executive Vice President
Laureen E. Seeger
Chief Compliance Officer, Executive Vice President, General Counsel
Jorge L. Figueredo
Executive Vice President - Human Resources
Patrick J. Blake
Executive Vice President, Group President
Paul Coleman Julian
Executive Vice President, Group President
Brian S. Tyler
Executive Vice President - Corporate Strategy and Business Development
 
Company Contact
Address: McKesson Plaza, One Post Street
SAN FRANCISCO CA 94104
Tel: 1-415-9838391
Website: www.mckesson.com
IR: www.mckesson.com/investors/stock-information/stock-information
Business Overview
McKesson Corporation delivers pharmaceuticals, medical supplies and healthcare information technologies. The Company operates in two segments: McKesson Distribution Solutions segment and McKesson Technology Solutions segment. The McKesson Distribution Solutions segment distributes drugs, medical-surgical supplies and equipment and health and beauty care products throughout North America. The McKesson Technology Solutions segment delivers enterprise clinical, patient care, financial, supply chain, strategic management software solutions, pharmacy automation for hospitals, as well as connectivity, outsourcing and other services, including remote hosting and managed services, to healthcare organizations. In February 2013, the Company completed acquisition of Pss World Medical Inc. In February 2014, McKesson Corporation announced that its ownership in Celesio AG exceeds 75% interest.
Financial Overview
For the nine months ended 31 December 2013, McKesson Corporation revenues increased 9% to $99.47B. Net income before extraordinary items decreased 8% to $992M. Revenues reflect Distribution Solutions segment increase of 9% to $97.09B, Technology Solutions segment increase of 8% to $2.37B. Net income was offset by Other As reported Operating Expenses increase of 18% to $2.58B (expense).
Employees: 43,500 as of Mar 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $41,565M as of Dec 31, 2013
Annual revenue (TTM): $130,088M as of Dec 31, 2013
EBITDA (TTM): $3,517M as of Dec 31, 2013
Net annual income (TTM): $1,251M as of Dec 31, 2013
Free cash flow (TTM): $2,032M as of Dec 31, 2013
Net Debt Last Fiscal Year: $2,443M as of Dec 31, 2013
Shares outstanding: 230,126,791 as of Dec 31, 2013
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
CVS Caremark (N:CVS)
Cardinal Health (N:CAH)
Express Scripts Holding C (OQ:ESRX)